Search
Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15709ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Zinc
go.drugbank.com/drugs/DB01593ApprovedInvestigationalIt is identified by the symbol _Zn_ [L2098]. … Understanding the mechanisms that control brain zinc homeostasis is, therefore, imperative to the development of preventive and treatment regimens for these and other neurological disorders [A32465].
Mixtures: T-PA Cap, TL-FluoriviteLonafarnib
go.drugbank.com/drugs/DB06448ApprovedInvestigational[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an … Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature
Lacosamide
go.drugbank.com/drugs/DB06218ApprovedInvestigationalLacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. … [A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008.
Rivastigmine
go.drugbank.com/drugs/DB00989ApprovedInvestigationalRivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type.
Mavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigational[L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4. … by a reduced number of mature neutrophils and lymphocytes.
Acetohydroxamic acid
go.drugbank.com/drugs/DB00551ApprovedInvestigationalIt is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections. … Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease.
Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15507ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Tasmania/503/2020 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16726ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Pitavastatin
go.drugbank.com/drugs/DB08860ApprovedInvestigational[A181409,A181535,A181538,A1793] Study data has confirmed that pitavastatin's potency in lowering LDL-C is comparable to that of other statins but also has increased efficacy in increasing HDL-C (also known … were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels.